The role of ErbB inhibitors in trastuzumab resistance

被引：26

作者：

Miller, KD ^{[1
]}

机构：

[1] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA

来源：

ONCOLOGIST | 2004年 / 9卷

关键词：

breast cancer; resistance; trastuzumab; tyrosine kinase receptor;

D O I：

10.1634/theoncologist.9-suppl_3-16

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The ErbB family of receptors and ligands is a complex, delicately balanced system involved in the growth and differentiation of normal human cells as well as neoplasms. Targeting this system with therapies that inhibit ErbB receptor activity in cancer patients has been somewhat successful, but resistance to ErbB inhibitor monotherapy is substantial. An understanding of the biology of ErbB receptor inhibitors is necessary to determine how best to utilize them in treatment regimens. Experimental evidence has provided valuable insights regarding mechanisms involved in resistance, and indicates that resistance can be reversed in some models. Ongoing studies in patients are evaluating whether agents that target both the epidermal growth factor (EGFR, ErbB-1) and ErbB-2 (HER-2) receptors can prevent or delay resistance in patients with metastatic breast cancer that overexpresses HER-2. With a better understanding of the biology of breast cancer, and with several novel ErbB receptor inhibitors in development, continued progress for improved patient outcomes is expected.

引用

页码：16 / 19

页数：4

共 12 条

[1]

Albain K, 2002, BREAST CANCER RES TR, V76, pS33

[2] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[3] Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer [J].

Esteva, FJ ;

Valero, V ;

Booser, D ;

Guerra, LT ;

Murray, JL ;

Pusztai, L ;

Cristofanilli, M ;

Arun, B ;

Esmaeli, B ;

Fritsche, HA ;

Sneige, N ;

Smith, TL ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1800-1808

[4]

Konecny Gottfried E., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1003

[5] ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation:: Receptor overexpression does not determine growth dependency [J].

Lane, HA ;

Beuvink, I ;

Motoyama, AB ;

Daly, JM ;

Neve, RM ;

Hynes, NE .

MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (09) :3210-3223

[6]

Massarweh S, 2002, BREAST CANCER RES TR, V76, pS33

[7]

Moulder SL, 2001, CANCER RES, V61, P8887

[8]

Robertson JFR, 2002, BREAST CANCER RES TR, V76, pS96

[9] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[10]

Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719

← 1 2 →